Abstract
Unlike systemic chemotherapy for hematological malignancies with hepatitis B virus (HBV) infection, transarterial chemoembolization (TACE) for HBV-related hepatocellular carcinoma (HCC) has only recently been reported to cause HBV reactivation and subsequent hepatitis. Most patients with HBV-related HCC have an underlying disease with liver fibrosis or cirrhosis, and TACE may potentially induce HBV reactivation and liver decompensation. Currently, there are no clinical guidelines for managing TACE-caused HBV reactivation. In this review, we summarize the changes of HBV status and liver function after TACE and the effect of antiviral treatment before, during, or after TACE.
Keywords:
Antiviral therapy; HBV reactivation; Hepatitis B virus; Hepatocellular carcinoma; Liver function; Nucleotide/nucleoside analogues; Transarterial chemoembolization.
MeSH terms
-
Adrenal Cortex Hormones / administration & dosage
-
Adrenal Cortex Hormones / adverse effects
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects*
-
Antiviral Agents / therapeutic use*
-
Carcinoma, Hepatocellular / therapy*
-
Chemoembolization, Therapeutic / adverse effects*
-
DNA, Viral / blood*
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Epirubicin / administration & dosage
-
Epirubicin / adverse effects
-
Hepatitis B Surface Antigens / blood
-
Hepatitis B virus / genetics
-
Hepatitis B, Chronic / blood
-
Hepatitis B, Chronic / etiology
-
Hepatitis B, Chronic / prevention & control*
-
Humans
-
Liver Neoplasms / therapy*
-
Rituximab / administration & dosage
-
Rituximab / adverse effects
-
Virus Activation*
Substances
-
Adrenal Cortex Hormones
-
Antineoplastic Agents
-
Antiviral Agents
-
DNA, Viral
-
Hepatitis B Surface Antigens
-
Epirubicin
-
Rituximab
-
Doxorubicin